Suchergebnisse - "Stein, Mark R."

1

Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies

von: Stein, Mark R.

2016, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
2

A New Liquid 10% Intravenous Immunoglobulin (IVIG) Administered with 15-Minute Titration Periods Allows Shorter Infusion Durations and Tolerability Similar to a 5% Formulation

von: Stein, Mark R.

2017, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
3

Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies

von: Stein, Mark R.

2008, in: Journal of clinical immunology

Wird geladen...
4

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy

von: Koterba, Alan P

2014, in: Allergy, asthma and clinical immunology

Wird geladen...
5

Patients with Rheumatologic Disorders May Develop Pain with Immunoglobulin Replacement, Requiring the Use of Daily Subcutaneous Therapy

von: Koterba, Alan

2015, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
6

Modified Oral Rapid Drug Desensitization (ORDD) to Ibrutinib in a Patient with Stage IV Mantle Cell Lymphoma and Early Onset Grade 1 Hypersensitivity Reaction

von: Perez, Elena E.

2017, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
7

Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates

von: Sleasman, John W.

2010, in: Journal of clinical immunology

Wird geladen...
8

Evaluation of the Safety, Tolerability, and Pharmacokinetics of $ Gammaplex^{®} $ 10% Versus $ Gammaplex^{®} $ 5% in Subjects with Primary Immunodeficiency

von: Wasserman, Richard L.

2017, in: Journal of clinical immunology

Wird geladen...
9

Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency

von: Wasserman, Richard L.

2017, in: Journal of clinical immunology

Wird geladen...
10

New Frontiers in Subcutaneous Immunoglobulin Treatment

von: Jolles, Stephen

2011, in: Biologics in therapy

Wird geladen...
11

Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency

von: Wasserman, Richard L.

2011, in: Clinical pharmacokinetics

Wird geladen...
12

Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies

von: Wasserman, Richard L.

2017, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
13

Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)

von: Gupta, Sudhir

2017, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
14

Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America

von: Suez, Daniel

2016, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
15

A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America

von: Suez, Daniel

2017, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
16

Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)

von: Wasserman, Richard L.

2015, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
17

Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over Time

von: Wasserman, Richard L.

2016, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
18

Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease

von: Wasserman, Richard L.

2011, in: Journal of clinical immunology

Wird geladen...
19

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

von: Wasserman, Richard L.

2016, in: Journal of clinical immunology

Wird geladen...
20

Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency

von: Church, Joseph A.

2006, in: Journal of clinical immunology

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!